Table 1.
MAb designation1 | |||||
---|---|---|---|---|---|
BF-F8 | SC-71 | BF-35 | RT-D9 | BF-F3 | |
Class | IgG | IgG | IgG | IgM | IgM |
Working dilution | 1: 200 | 1: 10 000 | 1: 10 000 | 1: 1000 | 1: 25 |
Specificity2 | All except | MHC-IID/X | |||
MHC-I | MHC-IIA | MHC-IID/X | and MHC-IIB | MHC-IIB | |
MHC content | MAb reactivity | ||||
I | + | − | + | − | − |
I + IIA | + | + | + | − | − |
IIA | − | + | + | − | − |
IIAD/X | − | + | + | + | − |
IID/X | − | − | − | + | − |
IID/XB | − | − | + | + | + |
IIB | − | − | + | + | + |
Source: S. Schiaffino, Padova, Italy.
According to Schiaffino et al. (1989). +, positive reaction for a MAb with a specific MHC-based fibre type. −, no reaction for a MAb and a specific MHC-based fibre type.